Syntis Bio has announced that results from its Phase 1/1b SYNTIETY-1 trial of SYNT-101, an investigational once-daily tablet for obesity, were presented at The Obesity Society’s 44th Annual Meeting at ObesityWeek® 2026. Data from the trial demonstrated that SYNT-101 reproduced the meal-driven gut-hormone response of gastric bypass surgery, produced placebo-adjusted weight loss o...
Receive updates from Bariatric News for free, starting right now.
We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.
This way you won't miss any new article from Bariatric News. Unsubscribe at any time.
Site title: Latest | Bariatric News